Do analysts recommend MDCX or THAR?

Medicus Pharma presently has a consensus price target of $9.00, indicating a potential upside of 2,061.90%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, MDCX or THAR?

Tharimmune is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicus Pharma N/A N/A -$35.46M -$2.68 N/A Tharimmune N/A N/A -$12.20M -$3.99 N/A

Is MDCX or THAR more profitable?

Tharimmune's return on equity of -588.45% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -311.33% Tharimmune N/A -588.45% -264.41%

Do analysts recommend LIXT or MDCX?

Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 2,061.90%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable valuation & earnings, LIXT or MDCX?

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is LIXT or MDCX more profitable?

Lixte Biotechnology's return on equity of -134.91% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% Medicus Pharma N/A -3,137.84% -311.33%

Does the media refer more to LIXT or MDCX?

In the previous week, Medicus Pharma had 1 more articles in the media than Lixte Biotechnology. MarketBeat recorded 2 mentions for Medicus Pharma and 1 mentions for Lixte Biotechnology. Medicus Pharma's average media sentiment score of 0.61 beat Lixte Biotechnology's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medicus Pharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BDTX or MDCX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -30.18% -23.91% Medicus Pharma N/A -3,137.84% -311.33%

Does the media refer more to BDTX or MDCX?

In the previous week, Medicus Pharma had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 2 mentions for Medicus Pharma and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.68 beat Medicus Pharma's score of 0.61 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medicus Pharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ETHZ or MDCX?

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,061.90%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Flag Ship Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is ETHZ or MDCX more profitable?

Flag Ship Acquisition's return on equity of -185.71% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Flag Ship Acquisition N/A -185.71% -83.12% Medicus Pharma N/A -3,137.84% -311.33%

Medicus Pharma (MDCX) Competitors

$0.42 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.42 +0.01 (+1.85%)

As of 07/2/2026 07:57 PM Eastern

Compare

MDCX vs. THAR, LIXT, BDTX, ETHZ, and ATRA

Should you buy Medicus Pharma stock or one of its competitors? MarketBeat compares Medicus Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medicus Pharma include Tharimmune (THAR), Lixte Biotechnology (LIXT), Black Diamond Therapeutics (BDTX), Flag Ship Acquisition (ETHZ), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry.

How does Medicus Pharma compare to Tharimmune?

Medicus Pharma (NASDAQ:MDCX) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

1.2% of Tharimmune shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by insiders. Comparatively, 6.7% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tharimmune's return on equity of -588.45% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Tharimmune	N/A	-588.45%	-264.41%

Medicus Pharma has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Medicus Pharma presently has a consensus price target of $9.00, indicating a potential upside of 2,061.90%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tharimmune is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

In the previous week, Medicus Pharma had 2 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for Medicus Pharma and 0 mentions for Tharimmune. Medicus Pharma's average media sentiment score of 0.61 beat Tharimmune's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Medicus Pharma	Positive
Tharimmune	Neutral

Summary

Medicus Pharma beats Tharimmune on 8 of the 13 factors compared between the two stocks.

How does Medicus Pharma compare to Lixte Biotechnology?

Lixte Biotechnology (NASDAQ:LIXT) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Lixte Biotechnology's return on equity of -134.91% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Lixte Biotechnology has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market.

5.1% of Lixte Biotechnology shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 2,061.90%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Medicus Pharma had 1 more articles in the media than Lixte Biotechnology. MarketBeat recorded 2 mentions for Medicus Pharma and 1 mentions for Lixte Biotechnology. Medicus Pharma's average media sentiment score of 0.61 beat Lixte Biotechnology's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lixte Biotechnology beats Medicus Pharma on 7 of the 13 factors compared between the two stocks.

How does Medicus Pharma compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Black Diamond Therapeutics presently has a consensus target price of $9.83, indicating a potential upside of 389.22%. Medicus Pharma has a consensus target price of $9.00, indicating a potential upside of 2,061.90%. Given Medicus Pharma's higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Black Diamond Therapeutics' return on equity of -30.18% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Medicus Pharma	N/A	-3,137.84%	-311.33%

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Black Diamond Therapeutics has higher revenue and earnings than Medicus Pharma. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.65	$22.37M	-$0.77	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

In the previous week, Medicus Pharma had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 2 mentions for Medicus Pharma and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.68 beat Medicus Pharma's score of 0.61 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medicus Pharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Black Diamond Therapeutics has a beta of 3.25, meaning that its stock price is 225% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market.

Summary

Black Diamond Therapeutics beats Medicus Pharma on 12 of the 15 factors compared between the two stocks.

How does Medicus Pharma compare to Flag Ship Acquisition?

Flag Ship Acquisition (NASDAQ:ETHZ) and Medicus Pharma (NASDAQ:MDCX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Flag Ship Acquisition's return on equity of -185.71% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flag Ship Acquisition	N/A	-185.71%	-83.12%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Flag Ship Acquisition has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flag Ship Acquisition	$4.11M	27.85	-$6.17M	-$159.65	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,061.90%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Flag Ship Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Medicus Pharma had 2 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 2 mentions for Medicus Pharma and 0 mentions for Flag Ship Acquisition. Medicus Pharma's average media sentiment score of 0.61 beat Flag Ship Acquisition's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Flag Ship Acquisition	Neutral
Medicus Pharma	Positive

Flag Ship Acquisition has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market.

4.1% of Flag Ship Acquisition shares are owned by institutional investors. 15.1% of Flag Ship Acquisition shares are owned by company insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Flag Ship Acquisition beats Medicus Pharma on 8 of the 14 factors compared between the two stocks.

How does Medicus Pharma compare to Atara Biotherapeutics?

Medicus Pharma (NASDAQ:MDCX) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Medicus Pharma has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atara Biotherapeutics' return on equity of -79.12% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

In the previous week, Medicus Pharma had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 2 mentions for Medicus Pharma and 0 mentions for Atara Biotherapeutics. Medicus Pharma's average media sentiment score of 0.61 beat Atara Biotherapeutics' score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Medicus Pharma	Positive
Atara Biotherapeutics	Neutral

70.9% of Atara Biotherapeutics shares are held by institutional investors. 8.1% of Medicus Pharma shares are held by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Medicus Pharma presently has a consensus price target of $9.00, suggesting a potential upside of 2,061.90%. Atara Biotherapeutics has a consensus price target of $9.50, suggesting a potential downside of 18.45%. Given Medicus Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Medicus Pharma is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Medicus Pharma has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than Medicus Pharma. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Atara Biotherapeutics	$120.77M	0.87	$32.69M	-$0.67	N/A

Summary

Atara Biotherapeutics beats Medicus Pharma on 8 of the 15 factors compared between the two stocks.

Get Medicus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDCX vs. The Competition

Export

Metric	Medicus Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.59M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.16	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	N/A	8.66	10.96	6.46
Net Income	-$35.46M	$23.81M	$3.57B	$337.01M
7 Day Performance	-9.10%	3.39%	2.12%	1.69%
1 Month Performance	18.94%	10.81%	5.25%	3.81%
1 Year Performance	-87.68%	62.61%	33.29%	23.90%

Medicus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDCX Medicus Pharma	3.4409 of 5 stars	$0.42 flat	$9.00 +2,061.9%	-87.7%	$23.59M	N/A	N/A	N/A	Short Interest Decrease Gap Down
THAR Tharimmune	N/A	$2.67 -17.5%	N/A	+54.7%	$100.55M	N/A	N/A	2
LIXT Lixte Biotechnology	0.2677 of 5 stars	$6.65 -3.2%	N/A	+174.2%	$99.88M	N/A	N/A	4
BDTX Black Diamond Therapeutics	3.7436 of 5 stars	$1.70 -8.6%	$10.00 +488.2%	-22.1%	$97.41M	$70M	N/A	90	Positive News
ETHZ Flag Ship Acquisition	N/A	$5.07 +0.8%	N/A	N/A	$96.39M	$4.11M	N/A	7	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDCX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medicus Pharma (MDCX) Competitors

MDCX vs. THAR, LIXT, BDTX, ETHZ, and ATRA

How does Medicus Pharma compare to Tharimmune?

Summary

How does Medicus Pharma compare to Lixte Biotechnology?

Summary

How does Medicus Pharma compare to Black Diamond Therapeutics?

Summary

How does Medicus Pharma compare to Flag Ship Acquisition?

Summary

How does Medicus Pharma compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medicus Pharma (MDCX) Competitors

MDCX vs. THAR, LIXT, BDTX, ETHZ, and ATRA

How does Medicus Pharma compare to Tharimmune?

Do insiders and institutionals believe in MDCX or THAR?

Is MDCX or THAR more profitable?

Which has more volatility and risk, MDCX or THAR?

Do analysts recommend MDCX or THAR?

Which has higher valuation & earnings, MDCX or THAR?

Does the media prefer MDCX or THAR?

Summary

How does Medicus Pharma compare to Lixte Biotechnology?

Is LIXT or MDCX more profitable?

Which has more volatility and risk, LIXT or MDCX?

Do insiders and institutionals have more ownership in LIXT or MDCX?

Which has preferable valuation & earnings, LIXT or MDCX?

Do analysts recommend LIXT or MDCX?

Does the media refer more to LIXT or MDCX?

Summary

How does Medicus Pharma compare to Black Diamond Therapeutics?

Do analysts rate BDTX or MDCX?

Is BDTX or MDCX more profitable?

Do institutionals and insiders have more ownership in BDTX or MDCX?

Which has better valuation & earnings, BDTX or MDCX?

Does the media refer more to BDTX or MDCX?

Which has more risk & volatility, BDTX or MDCX?

Summary

How does Medicus Pharma compare to Flag Ship Acquisition?

Is ETHZ or MDCX more profitable?

Which has higher valuation and earnings, ETHZ or MDCX?

Do analysts prefer ETHZ or MDCX?

Does the media refer more to ETHZ or MDCX?

Which has more risk and volatility, ETHZ or MDCX?

Do institutionals and insiders hold more shares of ETHZ or MDCX?

Summary

How does Medicus Pharma compare to Atara Biotherapeutics?

Is MDCX or ATRA more profitable?

Does the media prefer MDCX or ATRA?

Do institutionals & insiders believe in MDCX or ATRA?

Do analysts recommend MDCX or ATRA?

Which has more volatility & risk, MDCX or ATRA?

Which has stronger earnings and valuation, MDCX or ATRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools